ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,590 | -53.2% | 269 | -39.4% | 0.00% | -100.0% |
| Q2 2023 | $20,482 | +262.3% | 444 | +214.9% | 0.00% | – |
| Q1 2023 | $5,654 | -63.6% | 141 | -57.9% | 0.00% | -100.0% |
| Q4 2022 | $15,521 | +210.4% | 335 | +193.9% | 0.00% | – |
| Q3 2022 | $5,000 | -16.7% | 114 | +17.5% | 0.00% | – |
| Q2 2022 | $6,000 | +50.0% | 97 | +76.4% | 0.00% | – |
| Q1 2022 | $4,000 | -42.9% | 55 | -38.2% | 0.00% | – |
| Q4 2021 | $7,000 | – | 89 | +1680.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 5 | -28.6% | 0.00% | – |
| Q1 2021 | $1,000 | -50.0% | 7 | -75.0% | 0.00% | – |
| Q2 2019 | $2,000 | 0.0% | 28 | 0.0% | 0.00% | – |
| Q1 2019 | $2,000 | -83.3% | 28 | -90.6% | 0.00% | -100.0% |
| Q4 2018 | $12,000 | +200.0% | 298 | +547.8% | 0.00% | – |
| Q3 2018 | $4,000 | +33.3% | 46 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | +50.0% | 46 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 46 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | – | 46 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |